

### **REMARKS**

Upon entry of the present amendment, claims 1-9, 11-13, 48-49, 54-55, 59-60, 64-65, and 67-68 are pending in the application. Claims 10, 51-53, 56-58, 61-63, 66, and 69-71 have been withdrawn. Applicants reserve the right to prosecute the withdrawn subject matter, as well as the originally presented claims, in continuing applications. Applicants also reserve the right to rejoin the withdrawn claims drawn to non-elected species upon allowance of a generic claim. Claims 1-2, 11, 48-49, 54-55, 59-60, 64 and 67-68 have been amended. The present amendments are fully supported by the specification and the claims as originally filed. Accordingly, no new matter has been added by this filing.

### **Species Election**

Claims 1-13, 49, 55, 60, 64-66 and 68 have been found to be generic to the following species: (i) a reduced folate compound, cobalamin and NSAID combination; (ii) a reduced folate compound, cobalamin and a steroid combination; (iii) a reduced folate compound, cobalamin and an immunosuppressant combination; (iv) a reduced folate compound, cobalamin and cyclooxygenase inhibitor combination; (v) a folic acid or reduced folate compound cobalamin, NSAID and betaine combination; (vi) a folic acid or reduced folate compound, cobalamin, a steroid and betaine combination; (vii) a folic acid or reduced folate compound, cobalamin, an immunosuppressant and betaine combination; and (viii) a reduced folate compound, cobalamin, cyclooxygenase inhibitor and betaine combination.



The Examiner has requested the election of a single species of reduced folate compound or folic acid and NSAID, steroid, immunosuppressant or COX inhibitor. Applicants elect the reduced folate species 5-methyl-tetrahydrofolate and the NSAID species of ibuprofen, without traverse, for initial prosecution on the merits. Claims 1-9, 11-13, 48-49, 54-55, 59-60, 64-65, and 67-68 read on the elected species. Applicants request that upon allowance of a generic claim, such as, for example, claim 1, the Examiner consider all additional species which depend from or otherwise require all of the limitations of the allowable generic claim.

Applicants: Roubenoff et al.  
U.S.S.N. 10/020,634

### CONCLUSION

Applicants submit that the application is in condition for allowance and such action is respectfully requested. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact any of the undersigned at the telephone number provided below. The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No.21629-004.

Respectfully submitted,

   
Ingrid A. Beattie, Reg. No. 42,306  
Attorney for Applicant  
MINTZ, LEVIN, COHN, FERRIS  
GLOVSKY and POPEO, P.C.  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

ACTIVE 4088102v.1